Marketscan claims study of 62,813 IMID women w/ 70,529 pregnancies & 69,412 births, 4,485 (7.1%) were exposed to at least one TNFi during pregnancy & 3,559 postpartum. TNFi use NOT assoc w/ SIE risk during Preg (HR 1.39; 0.95-2.05) or postpartum (HR 1.22; https://t.co/NsxOLpT0ds

💬 #ACR25 Topic Panels — LIVE! Nov. 5 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: 👉 SpA Join Us Live on: X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss these discussions https://t.co/ARrEpN2ybC

GLP-1 and SGLT-2: Treatments Too Good to Ignore? Dr. Peter Nash reviews several studies presented on GLP-1s at #ACR25. He recommends for review abstracts: 0841, 0849, 1027, 2685, 0165, 0233 and 2658. https://t.co/OclO05bpku https://t.co/kASID9jnAP

B Cell Depletion: Check the Lymph Node Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25. https://t.co/BjgIC3Kng0 https://t.co/flfyLZYW8q

🌟 Wonderful news! One of the EMEUNET Top 10 Abstracts ACR 2025 has been accepted on Rheumatology! 🎊 Congratulations Erdem Bektas (@ebektasmd ) for this achievement! 👉You can read the manuscript in this link: https://t.co/teEscaBVG3 #EMEUNET https://t.co/BKRXTXiQ8U

Join us as we celebrate & congratulate, Eric L. Matteson, MD, MPH, recipient of the 2025 ACR Presidential Gold Medal Award! 🌟 VIEW → https://t.co/ZcIXeZbAKr @MayoClinic #ACR25 https://t.co/7G07K7ZkjS

🆕 Clinical Year in Review at #ACR25 By Dr. Bryant England @UNMC_Rheum 🔶 Review the most impactful studies in #Rheumatology from the past year! ❓ Any studies you would add to the list? #RheumX #RheumTwitter #ACR2025 https://t.co/rgOb4ZV4r8

Psoriatic Arthritis: Which biologic agent is the best first choice? A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease. https://t.co/pRMyPCvMrN https://t.co/nOgnf5F3Pw

Should we be using JAKi more in female SpA patients? In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of https://t.co/smLao0q2hv

💬 #ACR25 Topic Panels — LIVE! Nov. 4 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: CAR-T Join Us Live on: X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss these discussions https://t.co/zedho2RI6T

Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults In RA alone, nearly 40% of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental https://t.co/2pqXGURQtL

Tofacitinib in AxSpA in Developing Countries Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at #ACR25 https://t.co/4kTv90PhIC https://t.co/WRUBP0O21b

900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the https://t.co/DBoteUTavZ

Topline results of ALLEGORY study (Genentech) - 300 pt. phase 3 DBRPCT obinuntuzumab vs PBO in active SLE w/ SRI-4 primary outcome at wk 52. The anti-CD20, B-cell depleter, Rx met all efficacy endpoints primary and all key secondary endpoints. Gazyva was FDA approved last wk https://t.co/Wd6EFEjvGP